Subsequent Compound definition

Subsequent Compound means, as to EACH Taisho Activated Receptor, a subsequent CART Identified Compound developed by Taisho and/or Taisho's Licensee(s) subsequently to the preceding CART Identified Compound preceedingly developed for thesame or similar therapeutic indication as the preceding CART Identified Compound, that is developed after the receipt of Marketing Authorization for the preceding CART Identified Compound or that is simultaneously developed with the preceding CART Identified Compound with the intent to commercialize both Compounds. For the purpose of determination of such intent, a subsequent CART Identified Compound shall be deemed Subsequent Compound if Phase 3 Clinical Study thereof is started prior to the launch of the preceding CART Identified Compound.
Subsequent Compound means any Compound, other than NLG919 or a Next Generation Compound: (a) that is invented or otherwise the subject of [*] conducted, by or on behalf of Genentech or its Affiliate or Sublicensee, but excluding [*], whether solely or jointly, that occurs after the end of the Next Gen Research Term but during the Restriction Period; (b) that is [*] from a Third Party during the Restriction Period; or (c) that is an enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug of a Compound described in (a), (b) or (c) above.
Subsequent Compound means any Compound, other than NLG919 or a Next Generation Compound: (a) that is invented after the end of the Next Gen Research Term but during the Restriction Period by or on behalf of GNE or a Sublicensee, whether solely or jointly; (b) that is the [*] by or on behalf of GNE or a Sublicensee, whether solely or jointly, that occurs after the end of the Next Gen Research Term but during the Restriction Period, but excluding any such Compound that is a [*] at the time of such [*]; (c) to which [*] such Compound, or an [*] from a Third Party, whether directly or indirectly, during the Restriction Period; or (d) that is an enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or [*] of a Compound described in (a), (b), or (c) above. For clarity, Subsequent Compounds do not include Compounds that are (x) [*], or invented by or on behalf of, or that are the subject of [*] by or on behalf of, either (i) [*] (including through [*] that are not [*]) or (ii) [*] in the course of its activities conducted on [*] or otherwise [*] or (y) Roche Acquired Compounds as long as, in each case of (x) and (y), such Compound (1) does not [*], (2) and [*] are and were not [*] during the Restriction Period, (3) is not [*] above, and (4) was invented, [*], as applicable, without [*].

Examples of Subsequent Compound in a sentence

  • For a Subsequent Compound, the payment shall be made only at the first occurrence, if any, of a milestone set forth below as to the Drug Product first applicable to such milestone that incorporate the Subsequent Compound, regardless of formulation and/or indication of the Drug Product.

  • Taisho shall provide Notice to Arena of its decision to implement Taisho Development of a Subsequent Compound.

  • Arena acknowledges and agrees that Taisho shall have sole discretion to: (i) determine which CART Identified Compound to develop as a first Drug Product, Back-Up Compound or Subsequent Compound; and (ii) whether or not to continue development of any CART Identified Compound or Drug Product.

  • For a Drug Product comprising a Subsequent Compound that has received Marketing Authorization in the United States, Taisho shall provide Arena with an approval fee of [**********************************] within thirty (30) days of receipt of notification of such Marketing Authorization.

  • As part of the Development Information provided to NOVARTIS with respect to any Subsequent Candidate, VERTEX shall inform NOVARTIS whether it will propose that development of the Subsequent Compound be undertaken pursuant to a Joint Venture as described in Section 6.4.2 of the License Agreement, and if not, whether VERTEX will manufacture and supply Bulk Drug Product with respect to that Subsequent Candidate under Section 6.4.1 of the License Agreement.

  • For a Drug Product comprising a Subsequent Compound that has received Marketing Authorization in the United States, Taisho shall provide Arena with an approval fee of [******************* (*******)] within thirty (30) days of receipt of notification of such Marketing Authorization.

  • For a Drug Product comprising a Subsequent Compound that has received Marketing Authorization in the first European Country, Taisho shall provide Arena with an approval fee of [******************** (*******)] within thirty (30) days of receipt of notification of such Marketing Authorization.

  • For a Drug Product comprising a Subsequent Compound that has received Marketing Authorization in Japan, Taisho shall provide Arena with an approval fee of [**********************************] within thirty (30) days of receipt of notification of such Marketing Authorization.

  • For a Drug Product comprising a Subsequent Compound that has received Marketing Authorization in the first European Country, Taisho shall provide Arena with an approval fee of [**********************************] within thirty (30) days of receipt of notification of such Marketing Authorization.

  • For a Drug Product comprising a Subsequent Compound that has received Marketing Authorization in Japan, Taisho shall provide Arena with an approval fee of [******************* (*******)] within thirty (30) days of receipt of notification of such Marketing Authorization.


More Definitions of Subsequent Compound

Subsequent Compound means any Compound, other than NLG919 or a Next Generation Compound: (a) that is invented or otherwise the subject of [*] conducted, by or on behalf of Genentech or its Affiliate or Sublicensee, but excluding [*], whether solely or jointly, that occurs after the end of the Next Gen Research Term but during the Restriction Period; (b) that is [*] from a Third Party during the Restriction Period; or (c) that is an enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug of a Compound described in (a), (b) or (c) above. Confidential Execution Version